New findings presented at #ASCO26 suggest a new approach could help slow the growth of intermediate-stage liver cancer. An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa (@GABOUALFA) found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC). “By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: bit.ly/4x7vt7o

#ASCO2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #HER2 #RAS #BTC! Advanced Fellow Aruj Dhyani #YIA #ADC #BTC Assistant Attending @rohit_thum #MTAP #NET #BTC #PDAC. Glad to mentor, but grateful for what you teach me too!

Proud to see 18 MSK staff recognized as 2026 Conquer Cancer Grants & Awards recipients ahead of #ASCO26. Congratulations to this outstanding group helping advance the future of cancer research and care. 👏

Looking forward to joining faculty of this year #cancer #phase1 #HPB @myESMO @MSKCancerCenter

⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030. MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment. “This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.” Learn more about this research: bit.ly/4trr1xK @AACR

Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed

🔥off the press: EMERALD-3 Phase III trial positive. 👉Significant PFS benefit for STRIDE/Lenva TACE, trend of OS benefit 👉Trend for PFS benefit for STRIDE TACE 🧐Looking forward to see more details @myESMO @EASLedu @ILCAnews

Thank you @GABOUALFA, @MSK_DeptOfMed for many years of mentorship/support in #HPB cancers. Amazing to win this @theNCI #R01 award. @EileenMOReilly , @YJanjigianMD @DSolit @OlcaBasturk @MskccCMO @MSKBiostats @MSKCancerCenter

Congratulations @HardingJJMD on your #R01. @MSKCancerCenter @MSK_DeptOfMed and all colleagues are happy for you!

It was a great honor and delight for @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA and @HardingJJMD to join this superb teaching effort. Thanks @oncodaily for the opportunity

Great Ride for #Liver #bileduct #cancer! Thank Chris Crane and Matt McMillan for joining The LIVE Riders! @Cycle4Survival @MSK_DeptOfMed @MSKCancerCenter.

Great work @OrlaFitz10 Glad to mentor you and happy you are part of our #HPB team @MSKCancerCenter, @MSK_DeptOfMed Excellent editorial on #HER2 directed therapy in #biliarytractcancer. aacrjournals.org/clincancerr…

Support #Liver and #BileDuctCancer Research! We're participating in @Cycle4Survival to raise money for rare cancer research at @MSKCancerCenter, and your support would mean so much to us. Make a 100% tax-deductible donation using the link. Thank you! secure2.convio.net/mskcc/sit…

Fantastic panel discussion on the future of #HCC therapy with @MarkYarchoan @DrElkhoueiry @HardingJJMD @DJPinato @JosephFranses #richardfinn The near future is a “plateau” while we await the next breakthrough @AnjanaPillaiMD @docamitgs @laurakulik1 #livertwitter

Radiologists play a critical role in assessing systemic therapy response in liver cancers; this requires a comprehensive approach beyond size changes to support personalized management. @VChernyakMD @taehyung_rad @DrRichardDo @MishalLala @HardingJJMD bit.ly/45YVCcB

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in #PDAC @JNCI_Now doi.org/10.1093/jnci/djaf361 🔎NRG1 pts at Memorial Sloan Kettering 👉76,531 pts > 48 NRG1 cases 👉Young pts, enriched in RAS WT PDAC 👉RNA testing is key @myESMO

Final Results from a First-in-Human Phase I Study of the Dual IDH 1/2 Inhibitor, LY3410738, in Solid Tumors Harboring IDH1 or IDH2 Mutations @CCR_AACR doi.org/10.1158/1078-0432.CC… 🔎119 pts mono, 19 pts with CISGEM 👉ORR 5.2% & 11.1% 👉LY3410738 CISGEM in BTC: ORR 42%, mPFS 8mo 🧐Could be interesting in BTC @myESMO @EASLedu

Fantastic international conference @GABOUALFA. Always great learning opportunities. @MSKCancerCenter @MSK_DeptOfMed

For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/3LX1GuL

Agree, reflex HER2 IHC for all patients with biliary tract cancer. @MSKCancerCenter @MSK_DeptOfMed